Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
Launched by BAYER · May 9, 2007
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
The trial is sponsored by Bayer Schering Pharma AG, Germany.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy female volunteers, aged 18 - 35 years (smokers up to 30 years)
- • Willingness to apply non-hormonal methods of contraception during the course of the study (e.g., condom with spermicide, diaphragm with spermicide)
- • Confirmation of ovulation during the cycle before treatment
- • Normal routine blood values
- Exclusion Criteria:
- • Contraindications for the use of oral contraceptives
- • Pregnancy, lactation
- • Simultaneous participation in another clinical study
- • Considerable overweight
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Berlin, , Germany
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials